Furthermore, to examine whether Glrx has a complemental anti-fibrotic effect whereby dietary changes improve obesity and fatty liver, we injected AAVs at 20 weeks and then changed diet at 28 weeks (Figure 6A). This evidence concerns the gene GLRX and obesity due to melanocortin 4 receptor deficiency.